Imatinib-induced erythroderma mediated by an unusual non-dose-dependent mechanism [2]

European Journal of Dermatology

Volumn 17, Issue 6, 2007, Pages 538-539

  Vano Galvan, Sergio ^a   Fernandez Guarino, Monserrat ^a   Henriquez Santana, Aythamy ^a   De Las Heras, Elena ^a   Calbacho, Maria ^a   Jaen, Pedro ^a  

^a HOSPITAL RAMÓN Y CAJAL   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; DASATINIB; IMATINIB; PREDNISONE;

AGED; CASE REPORT; CHRONIC MYELOID LEUKEMIA; CLINICAL FEATURE; DRUG INDUCED DISEASE; ERYTHRODERMA; HUMAN; LETTER; MALE; PHYSICAL EXAMINATION;

AGED; ANTINEOPLASTIC AGENTS; DERMATITIS, EXFOLIATIVE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ERUPTIONS; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; PIPERAZINES; PYRIMIDINES; SKIN;

EID: 36749075610     PISSN: 11671122     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Letter

References (6)

1. Sanchez-Gonzalez B, Pascual-Ramirez JC, Fernandez-Abellan P, Belinchon-Romero I, Rivas C, Vegara-Aguilera G. Severe skin reaction to imatinib in a case of Philadelphia-positive acute lymphoblastic leukemia. Blood 2003; 101: 2446.
2. Drummond A, Micallef-Eynaud P, Douglas WS, Hay I, Holyoake TL, Drummond MW. A spectrum of skin reactions caused by the tyrosine kinase inhibitor imatinib mesylate (STI 571, Glivec). Br J Haematol 2003; 120: 911-3.
3. Brazzelli V, Prestinari F, Roveda E, Barbagallo T, Bellani E, Vassallo C, Orlandi E, Passamonti F, Borroni G. Pityriasis rosea-like eruption during treatment with imatinib mesylate: description of 3 cases. J Am Acad Dermatol 2005; 53 (5 Suppl 1): S240-S243.
4. Ugurel S, Hildenbrand R, Dippel E, Hochhaus A, Schadendorf D. Dose-dependent severe cutaneous reactions to imatinib. Br J Cancer 2003; 88: 1157-9.
5. Nelson RP, Jr., Cornetta K, Ward KE, Ramanuja S, Fausel C, Cripe LD. Desensitization to imatinib in patients with leukemia. Ann Allergy Asthma Immunol 2006; 97: 216-22.
6. Peggs K, Mackinnon S. Imatinib mesylate-the new gold standard for treatment of chronic myeloid leukemia. N Engl J Med 2003; 348: 1048-50.